About Us

Rocket Isotopes is part of the Swiss Rockets Group, a leading Swiss biotech incubator and a prominent player in drug research across oncology and chronic diseases, with a diversified portfolio of products advancing through clinical stages.

MISSION

To develop a clear avenue for Tb-161 supply to cater to demand for patients needing radioligand therapies to treat cancer and other diseases.

VISION

A future where people with cancer can all access best-in-class treatments.

Swiss Rockets AG

Torpedo Pharmaceuticals AG

Team – Leadership

Dr. Vladimir Cmiljanovic

Chief Executive Officer

Dr. Nadezda Gracheva

Chief Operating Officer

Christoph Bütikofer

Chief Business Officer

Prof. Dr. Andreas Türler

Chief Radiochemist

Andreas Emmenegger

Chief Financial Officer

Dr. Carlo Durrer

Chief Quality Officer

Dr. Milan Crnogorac

Chief Technology Officer

Johan Wisenborn

Chief Legal Officer